Compound
One ampoule contains 1 milliliter of solution, which contains 2-ethyl-6-methyl-3-hydroxypyridine hydrochloride ( emoxipine ). Ampoules are used to administer Emoxipine intramuscularly or intravenously.
Emoxipin 1, which is used in ophthalmology, has a similar composition of the active substance, but differs in the form of release: the ampoules are replaced by more convenient bottles with dispensers at the end, which allows you to measure exactly one drop of the substance for each eye.
pharmachologic effect
Emoxipine (INN - Emoxipine) is an angioprotector that reduces the level of permeability of vascular walls by accelerating free radical processes; the drug is also an antioxidant and antihypoxic agent . Emoxipine will reduce the level of blood viscosity, the permeability of vascular walls and the tendency to develop hemorrhages. In addition, the active ingredients of the drug will increase the level of cyclic nucleotides in brain tissue and blood platelets.
The fibrinolytic activity of the drug is manifested in the fact that in the case of an acute period of a heart attack , the drug is able to dilate the coronary vessels, thereby limiting the developing focus of necrosis . Also, the conduction and contractility of the heart will be improved.
As an ophthalmic substance, Emoxipin has retinoprotective properties; it protects the retina from the action of high-intensity light rays. Emoxipin drops will help resolve intraocular hemorrhages and improve microcirculation in the eye.
Pharmacodynamics and pharmacokinetics
Pharmacodynamics
Positive effect on blood coagulation : by reducing the overall coagulation index and reducing the process of platelet aggregation, the drug prolongs blood clotting time. Under the influence of the drug, the membranes of cells and blood vessels are stabilized, red blood cells increase their resistance to hemolysis and potential mechanical injuries.
Effective inhibition of free radical oxidation of lipids contained in biomembranes. Increased activity of enzymes responsible for antioxidant function. Able to have a lipid-lowering effect by reducing the synthesis of triglycerides.
Taking Emoxipine can reduce the manifestations of cerebral hemodysfunction . Has a positive effect on the resistance of the cerebral cortex to ischemia and hypoxia . Corrects autonomic dysfunctions in cases of cerebrovascular accident.
Emoxipine has a clear cardioprotective effect. The cardiovascular system will be protected in case of ischemic myocardial damage : the medicine blocks its spread, also dilating the coronary vessels.
As eye drops, Emoxipin protects the retina from potential damage due to exposure to high-intensity light rays. In addition, thanks to the drug, it is possible to resolve hemorrhages inside the eye.
Pharmacokinetics
In the case of intravenous administration of a dose of 10 mg per 1 kg of patient weight, a very low half-elimination rate of the drug . Elimination constant - 0.041 min; apparent volume of distribution - 5.2 l; total clearance rate is 214.8 ml per minute.
metabolism occurs .
The pharmacokinetics of Emoxipine may vary depending on the patient's condition. For example, in the case of a pathological condition of coronary occlusion , the rate at which the drug is eliminated will be reduced, making it more bioavailable.
In the case of retrobulbar administration of Emoxipine, the active ingredients of the drug appear in the blood almost immediately, a consistently high level remains for two hours, and 24 hours after administration, the trace of administration is practically completely absent in the blood. A certain concentration of the drug remains in the eye tissues.
Description and effect of the product
In the drug emoxipine, the instructions indicate this, the active ingredient is methylethylpyridinol hydrochloride. The product is produced in the form of a solution and can be packaged in ampoules or 5 ml bottles equipped with a pipette.
When used, Emoxipine has the following effects:
- Antioxidant. This helps prevent the negative effects of free radicals on cell membranes.
- Antihypoxic, which is aimed at increasing tissue resistance to hypoxia.
- Angioprotective. The product strengthens the walls of blood vessels, improves microcirculation and metabolic processes.
- Antiaggregation. Thanks to it, it is possible to reduce the risk of platelets sticking together and reduce the likelihood of blood clots.
The main effect of emoxipine eye drops is to strengthen vascular membranes and reduce the tendency to hemorrhage. When using the product, the level of intraocular fluid is normalized. Also, emoxipin eye drops, the instructions for use indicate this, help resolve minor hemorrhages inside the eye.
When using emoxipin eye drops, it is possible to:
- Stabilize and strengthen the cell membranes in the membranes of the eyes.
- Improve blood microcirculation, against the background of which the processes of oxygen saturation of tissues are activated.
- Increase eye resistance to bright sunlight and other negative factors.
- Reduce blood viscosity and the rate of blood clotting.
- Optimize oxidative processes in mucous membranes and reduce the number of free radicals.
- Block the synthesis of prostaglandins and leukotrienes, which contribute to inflammation.
- Increase energy potential at the cellular level and metabolism.
The medicine can be used for intramuscular or intravenous administration. Emoxipine injections dilate the blood vessels of the heart, so they are often prescribed in the treatment of myocardial infarction. Also, infusions and injections are indicated to increase the brain's resistance to hypoxia.
Indications for use of Emoxipin
Indications for use as eye drops are:
- intraocular hemorrhages;
- thrombosis in the central retinal vein and its branches;
- glaucoma;
- protection of the retina after laser coagulation and high-intensity light (in case of sun and laser burns).
Indications for the use of Emoxipin injections:
- diabetic retinopathy;
- complicated myopathy;
- central chorioretinal dystrophies.
Emoxipin injections are also used in cases of chronic and acute cerebral circulatory disorders , if the cause of these disorders is hemorrhagic and ischemic disorders. If necessary, the drug can be administered either as an intramuscular injection or as an intravenous injection in ampoules.
Indications for eye drops
The main indication for emoxipine eye drops is hemorrhages in the eye of various origins. The drug is used for treatment if thrombosis of the central vein of the retina is diagnosed. This pathology is often associated with age, but can develop in young patients as a complication after suffering from influenza or other infectious disease.
The drug is also prescribed for other eye pathologies:
- Diabetic retinopathy, which affects the small vessels of the eye due to excessive blood sugar levels.
- Myopia and glaucoma in a complicated form, when it is necessary to relieve eye strain.
The drug is indicated for the treatment of corneal burns. When using eye drops, it is possible to reduce the intensity of pain, lacrimation, photophobia and speed up the healing process. The drug allows you to improve blood circulation when wearing contact lenses and reduce the impact of harmful negative factors.
As a preventative measure, eye drops are prescribed after surgery. Emoxipine slows down the development of dystrophic changes in the retina and inflammatory processes in the cornea. The product is indicated for use to reduce the risk of cataracts after 40 years.
Instructions for use of Emoxipin (Method and dosage)
Instructions for Emoxipin - eye drops
In the case of retrobulbar administration of the drug, a one percent solution in a dosage of 0.5 ml is administered once a day for 10–15 days. If the medicine is administered subconjunctivally and parabulbarly, then 0.2 to 0.5 ml of the drug is administered once a day for 10–30 days.
If it is necessary to protect the retina, the drug is administered retrobulbarly in a dosage of 0.5 ml per day and one hour before laser coagulation. The course depends on the degree of burns received during laser coagulation; in most cases, retrobulbar drops are used once a day for two to ten days.
Instructions for Emoxipin - solution for injection
In cardiology and neurology, the drug is mainly used intravenously using a dropper, at a rate of 20–40 drops per minute. The dose of the drug is 20-30 ml of a three percent solution. Droppers can be placed one to three times a day for 5–15 days. The duration of treatment directly depends on the type of patient’s disease. At the end of the drips, they switch to intramuscular injections of the drug: 3-5 ml of a 3% solution are administered 2-3 times a day. The course of intramuscular administration ranges from 10 to 30 days.
Emoxipine is not produced in tablet form, so you cannot take Emoxipine tablets, because they simply do not exist.
Emoxipin-Belmed solution for IV and IM administration 30 mg/ml 10 ml No. 1
Name
Emoxipin-Belmed.
Description
Transparent colorless or slightly yellowish solution.
Main active ingredient
Emoxipin.
Release form
5 ml in ampoules in blister packaging No. 5x1, No. 5x2 or in 10 ml bottles in packaging No. 1, No. 40.
pharmachologic effect
It is an inhibitor of free radical processes, an antihypoxant and an antioxidant. Reduces blood viscosity and platelet aggregation, increases the content of cyclic nucleotides (cAMP and cGMP) in platelets and brain tissue, has fibrinolytic activity, reduces the permeability of the vascular wall and the risk of hemorrhage, promotes their resorption. Dilates coronary vessels, in the acute period of myocardial infarction, limits the size of the necrosis focus, improves the contractility of the heart and the function of its conduction system. With high blood pressure (BP) it has a hypotensive effect. In acute ischemic disorders of cerebral circulation, it reduces the severity of neurological symptoms and increases tissue resistance to hypoxia and ischemia.
Pharmacokinetics
When administered intravenously at a dose of 10 mg/kg, the half-life of T1/2 is 18 minutes; total CI clearance - 0.2 l/min; apparent volume of distribution Vd - 5.2 l. The drug quickly penetrates into organs and tissues, where it is deposited and metabolized. Five metabolites of emoxypine were discovered, represented by dealkylated and conjugated products of its transformation. Metabolites of emoxipine are excreted by the kidneys. 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found in significant quantities in the liver. In pathological conditions, for example, in the case of coronary occlusion, the pharmacokinetics of emoxypine changes. The rate of elimination decreases and the time spent by emoxipine in the bloodstream increases, which may be due to its return from the depot, including from the ischemic myocardium.
Indications for use
As part of combination therapy: In neurology and neurosurgery: hemorrhagic stroke in the recovery period, ischemic stroke in the internal carotid artery and in the vertebrobasilar system, transient cerebrovascular accidents, chronic cerebral circulatory failure, traumatic brain injury accompanied by brain contusions; postoperative period in patients with traumatic brain injury, operated on for epidural, subdural and intracerebral hematomas, combined with brain contusions; pre- and postoperative period in patients with arterial aneurysms and arteriovenous malformations of cerebral vessels. In cardiology: acute myocardial infarction, prevention of “reperfusion syndrome”, unstable angina.
Directions for use and doses
Doses and duration of treatment are determined individually. In neurology and neurosurgery, emoxipine is used intravenously in a daily dose of 5–10 mg/kg for 10–12 days. Before administration, emoxipine is diluted in 200 ml of isotonic sodium chloride solution. Inject at a rate of 20 - 30 drops per minute. Subsequently, they switch to intramuscular administration of 2 - 10 ml of a solution of 30 mg/ml emoxypine (60 - 300 mg) 2 - 3 times a day for 10-30 days. In cardiology, they begin with intravenous drip (20 - 40 drops per minute) administration of 20 - 30 ml of a solution of 30 mg/ml emoxypine (600 - 900 mg) in 200 ml of isotonic sodium chloride solution 1 - 3 times a day for 5 - 15 days depending on the course of the disease, followed by a transition to intramuscular administration of 2 - 10 ml of a solution of 30 mg/ml emoxipine (60-300 mg) 2 - 3 times a day for 10 - 30 days. Treatment with emoxipine, in the case of intravenous and intramuscular administration, should be carried out under the control of blood pressure and the functional state of the blood coagulation and anticoagulation systems.
Use during pregnancy and lactation
Use during pregnancy and lactation is contraindicated.
Precautionary measures
It is necessary to constantly monitor blood pressure and blood clotting during treatment. Impact on the ability to drive vehicles and other potentially dangerous mechanisms. During treatment, it is necessary to refrain from engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Interaction with other drugs
Emoxipine is pharmaceutically incompatible with other drugs, therefore mixing in the same syringe or infusion pump with other injectable drugs is not allowed.
Contraindications
Increased individual sensitivity to emoxipine, pregnancy, lactation, children under 18 years of age. With caution: in patients with impaired hemostasis, during surgery or in patients with symptoms of severe bleeding (due to the effect on platelet aggregation).
Compound
Active substance – emoxipine – 150.0 mg/300.0 mg; excipients - sodium sulfite anhydrous, disodium phosphate dihydrate, water for injection.
Overdose
In case of overdose, the severity of the side effects of the drug may increase. Symptoms: increased blood pressure, agitation or drowsiness, headache, pain in the heart, nausea, discomfort in the epigastric region. Possible bleeding disorder. Treatment: symptomatic therapy, there is no specific antidote.
Side effect
With intravenous administration, a burning sensation may occur along the vein; Increased blood pressure, agitation or drowsiness, and blood clotting disorders may occur. In rare cases, headache, pain in the heart, nausea, discomfort in the epigastric region, itching and redness of the skin are possible.
Storage conditions
Store in a place protected from light at a temperature not exceeding 25 °C. Keep out of the reach of children.
Buy Emoxipin-Belmed solution for intravenous, intramuscular administration. 30 mg/ml in 10 ml bottle in pack No. 1 in the pharmacy
Price for Emoxipin-Belmed solution for intravenous, intramuscular injection, 30 mg/ml in 10 ml bottle in pack No. 1
Instructions for use for Emoxipin-Belmed solution for intravenous, intramuscular injection, 30 mg/ml in 10 ml bottle in pack No. 1
Overdose
In case of overdose of the drug, side effects may appear or increase. In case of an overdose of the drug or its analogues, blood pressure , excessive agitation or drowsiness , pain in the cardiac region, headache, nausea , and abdominal discomfort may appear. Blood clotting may be impaired.
Treatment of an overdose of Emoxipine and Emoxipine analogues consists of discontinuing the drug and carrying out symptomatic therapy procedures if necessary.
Contraindications and negative reactions
An absolute contraindication to the use of emoxipine solution is hypersensitivity to its components. This means that you must carefully read the composition of the spray.
Do not use the medicine for treatment under 18 years of age, during pregnancy and lactation. To minimize the risks of chronic diseases, emoxipine is prescribed with caution to elderly people. With intravenous invasions, complications may arise in the event of hemostasis disturbances during surgical operations, as well as in patients with signs of severe bleeding.
Side effects when using eye drops often include burning and itching. Swelling and hyperemia of the conjunctiva may also appear.
When administered intravenously, in addition to negative reactions at the injection site in the form of itching and burning, drowsiness and increased blood pressure may occur. In the presence of diseases of the digestive system, discomfort in the epigastric region and nausea are sometimes observed during the use of the medicine. Rare side effects include headache and discomfort in the heart area.
Reviews
Emoxipin is a highly effective modern remedy. Its only drawback is severe local irritation when used. People facing serious ophthalmological diseases leave extremely positive reviews about Emoxipin, because they strictly follow the doctor’s instructions and, due to the seriousness of the problem, clearly understand the need for treatment. If the drug is used for the treatment of minor ophthalmological disorders, then reviews of the drops will not be so positive: the fact is that not every person is ready to put up with temporary unpleasant burning sensations after taking the drug.
Reviews from doctors about eye drops are extremely positive. The drug copes with its task perfectly, although it causes temporary discomfort in patients.
Emoxipin injections effectively counteract the effects of strokes and heart attacks in many patients around the world. Also, taking the drug helps to reduce various manifestations of neurological disorders in a short period of time. It is logical that such a positive experience of use is reflected in positive reviews from both patients and doctors.
Emoxipin price, where to buy
You can buy Emoxipin in Kyiv without any problems: the drug or its analogues can be found in almost every pharmacy. But the cost may vary slightly depending on the pharmacy, however, almost all eye drops in Ukraine, and other drugs, vary in price. This depends not only on the pharmacy’s markup on the drug, but also on the place of its production, production batch, etc.
The average price of Emoxipin 1% eye drops in a 5 ml bottle fluctuates on the market around 60 UAH. A package of five ampoules of 1 ml of one percent Emoxipin No. 10 will cost about 50 UAH in a pharmacy.
- Online pharmacies in RussiaRussia
- Online pharmacies in UkraineUkraine
- Online pharmacies in KazakhstanKazakhstan
ZdravCity
- Emoxipin eye drops 1% fl.
5mlEnzyme LLC RUB 239 order - Emoxipine solution for in. 1% 1ml 10 pcs Federal State Unitary Enterprise Moscow Endocrine Plant
RUB 328 order
Pharmacy Dialogue
- Emoxipin (vial 1% 5ml No. 1 (cap.)) Enzyme LLC
RUB 215 order
- Emoxipin (vial 1% 5ml No. 1 (opening cap.)) Moscow Endocrine Plant
RUB 221 order
- Emoxipin (amp. 1% 1ml No. 10) Moscow Endocrine Plant
RUB 316 order
- Methylethylpyridinol (Emoxipin) (d/in solution 10 mg/ml amp 1 ml N10) Ellara LLC
116 RUR order
show more
Pharmacy24
- Emoxipin 1% 1 ml No. 10 injection solution AT "Lekhim-Kharkiv", Ukraine
138 UAH.order
PaniPharmacy
- Emoxipin ampoule Emoxipin solution d/in. 1% No. 10 Ukraine, Lekhim-Kharkov CJSC
166 UAH order
show more
